# Johnson & Johnson vs Novartis: stocks compared

URL: https://funkfolio.com/compare/jnj-vs-nvs

> Johnson & Johnson ($670.9B, P/E 42.9) and Novartis ($300.5B, P/E 30.4) compared: size, valuation, margins, debt, cash and price change.

---

## Johnson & Johnson vs Novartis

Johnson & Johnson (JNJ), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Johnson & Johnson is worth $670.9B on the stock market and Novartis $300.5B: Johnson & Johnson is valued at 2.2 times as much. Johnson & Johnson trades at 42.9 times earnings and Novartis at 30.4. Over the past year Johnson & Johnson's share price has moved +41.3% and Novartis's +25.1%.

### Key facts

- **Johnson & Johnson market value:** $670.9B
- **Novartis market value:** $300.5B
- **Johnson & Johnson P/E:** 42.9
- **Novartis P/E:** 30.4
- **Johnson & Johnson revenue:** $94.2B FY to 2025-12-28
- **Novartis revenue:** $54.5B FY to 2025-12-31
- **Superinvestors holding both:** 8

Market values as of 18 Nov 2026, 03:12 UTC.

Johnson & Johnson vs Novartis: every measure side by side

| Measure | Johnson & Johnson | Novartis |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | Switzerland |
| Fiscal year ends | 2025-12-28 | 2025-12-31 |
| Size |  |  |
| Market cap | $670.9B higher | $300.5B lower |
| Revenue | $94.2B higher | $54.5B lower |
| Earnings | $26.8B higher | $14B lower |
| Employees | 138,200 higher | 75,267 lower |
| Total assets | $199.2B higher | $110.9B lower |
| Valuation |  |  |
| P/E | 42.9 higher | 30.4 lower |
| P/S | 7.1 higher | 5.5 lower |
| P/B | 8.2 | — |
| Dividend yield | 1.87% | — |
| Profitability |  |  |
| Operating margin | — | 32.4% |
| Balance sheet |  |  |
| Net assets | $81.5B higher | $46.1B lower |
| Total liabilities | $117.7B higher | $64.4B lower |
| Total debt | $47.9B higher | $28.7B lower |
| Cash on hand | $19.7B higher | $11.4B lower |
| Price change |  |  |
| Today | -1.36% lower | -0.67% higher |
| 1 year | +41.3% higher | +25.1% lower |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Johnson & Johnson 139.6, Novartis 121.0.

- Johnson & Johnson (JNJ)
- Novartis (NVS)

Johnson & Johnson and Novartis share prices over one year, rebased to 100: Johnson & Johnson ends at 139.6, Novartis at 121.0.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | JNJ | NVS |
| --- | --- | --- |
| Nov 28, 2025 | 103.7 | 99.1 |
| Dec 31, 2025 | 103.7 | 104.8 |
| Jan 30, 2026 | 113.9 | 113.0 |
| Feb 27, 2026 | 124.5 | 128.2 |
| Mar 31, 2026 | 122.5 | 116.1 |
| Apr 30, 2026 | 115.2 | 112.4 |
| May 29, 2026 | 112.9 | 114.2 |
| Jun 30, 2026 | 127.3 | 119.1 |
| Jul 31, 2026 | 128.4 | 118.7 |
| Aug 31, 2026 | 133.2 | 115.6 |
| Sep 30, 2026 | 132.6 | 108.4 |
| Oct 30, 2026 | 136.9 | 122.2 |
| Nov 17, 2026 | 139.6 | 121.0 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (8)

- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 4.1% / 0.8%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 4.0% / 0.1%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 1.1% / 0.7%
- [Andrew Spokes](https://funkfolio.com/gurus/farallon) 0.7% / 0.2%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.3% / 0.2%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) 0.1% / &lt;0.1%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) &lt;0.1% / &lt;0.1%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) &lt;0.1% / 0.1%

#### Johnson & Johnson only (15)

- [Stephen Yacktman](https://funkfolio.com/gurus/stephen-yacktman) 4.0%
- [Mark Boyar](https://funkfolio.com/gurus/mark-boyar) 2.6%
- [Tom Gayner](https://funkfolio.com/gurus/tom-gayner) 1.3%
- [Fred DiSanto](https://funkfolio.com/gurus/fred-disanto) 1.1%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) 0.9%
- [Ray Dalio (founder)](https://funkfolio.com/gurus/bridgewater) 0.7%
- [Cliff Asness](https://funkfolio.com/gurus/cliff-asness) 0.3%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.2%
- [Mario Gabelli](https://funkfolio.com/gurus/mario-gabelli) 0.2%
- [George Soros](https://funkfolio.com/gurus/george-soros) 0.1%
- [Jensen team](https://funkfolio.com/gurus/jensen-investment) 0.1%
- [John Rogers](https://funkfolio.com/gurus/john-rogers) 0.1%
- [Christopher Bloomstran](https://funkfolio.com/gurus/christopher-bloomstran) &lt;0.1%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) &lt;0.1%
- [Thomas Russo](https://funkfolio.com/gurus/thomas-russo) &lt;0.1%

#### Novartis only (5)

- [Primecap team](https://funkfolio.com/gurus/primecap) 0.6%
- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 0.4%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 0.3%
- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 0.3%
- [Lee Ainslie](https://funkfolio.com/gurus/lee-ainslie) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Johnson & Johnson / Novartis). [Who owns JNJ](https://funkfolio.com/stock/JNJ/superinvestors) · [Who owns NVS](https://funkfolio.com/stock/NVS/superinvestors)

### More on Johnson & Johnson

- [Johnson & Johnson (JNJ) stock page](https://funkfolio.com/stock/JNJ)
- [Johnson & Johnson market cap](https://funkfolio.com/stock/JNJ/market-cap)
- [Johnson & Johnson revenue](https://funkfolio.com/stock/JNJ/revenue)
- [Johnson & Johnson P/E ratio](https://funkfolio.com/stock/JNJ/pe-ratio)
- [Johnson & Johnson operating margin](https://funkfolio.com/stock/JNJ/operating-margin)
- [Johnson & Johnson total debt](https://funkfolio.com/stock/JNJ/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Novartis

- [Novartis (NVS) stock page](https://funkfolio.com/stock/NVS)
- [Novartis market cap](https://funkfolio.com/stock/NVS/market-cap)
- [Novartis revenue](https://funkfolio.com/stock/NVS/revenue)
- [Novartis P/E ratio](https://funkfolio.com/stock/NVS/pe-ratio)
- [Novartis operating margin](https://funkfolio.com/stock/NVS/operating-margin)
- [Novartis total debt](https://funkfolio.com/stock/NVS/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Johnson & Johnson against its closest peers

- [Johnson & Johnson vs AbbVie](https://funkfolio.com/compare/abbv-vs-jnj)
- [Johnson & Johnson vs Eli Lilly](https://funkfolio.com/compare/jnj-vs-lly)
- [Johnson & Johnson vs Merck & Co](https://funkfolio.com/compare/jnj-vs-mrk)
- [Johnson & Johnson vs UnitedHealth Group](https://funkfolio.com/compare/jnj-vs-unh)

#### Novartis against its closest peers

- [Novartis vs AstraZeneca](https://funkfolio.com/compare/azn-vs-nvs)
- [Novartis vs UnitedHealth Group](https://funkfolio.com/compare/nvs-vs-unh)
- [Novartis vs Merck & Co](https://funkfolio.com/compare/mrk-vs-nvs)
- [Novartis vs Thermo Fisher Scientific](https://funkfolio.com/compare/nvs-vs-tmo)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Johnson & Johnson or Novartis?**

By market value, Johnson & Johnson is the larger: $670.9B against $300.5B for Novartis. By revenue in its latest fiscal year, Johnson & Johnson is the larger: $94.2B against $54.5B for Novartis.

**Which has the higher P/E ratio?**

Johnson & Johnson: 42.9, against 30.4 for Novartis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has more debt?**

Johnson & Johnson: $47.9B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Johnson & Johnson and Novartis?**

In their latest 13F filings, Tweedy, Browne team, Jeremy Grantham (co-founder), Ken Fisher, Andrew Spokes, Charles Brandes (founder), Murray Stahl, Rajiv Jain and Dodge & Cox team hold both.

### Cite this page

Funkfolio, “Johnson & Johnson vs Novartis”, data as of 18 November 2026. https://funkfolio.com/compare/jnj-vs-nvs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
